Literature DB >> 6329465

Dynorphin1-13: interaction with other opiate ligand bindings in vitro.

J Garzón, P Sánchez-Blázquez, J Gerhart, H H Loh, N M Lee.   

Abstract

Dynorphin1-13 is a potent inhibitor of electrically-induced contractions in the guinea pig ileum, where it has the properties of kappa-(ethylketocyclazocine) type opioids. In the brain, however, it has no analgesic potency, yet inhibits that induced by morphine. To gain further insight into its mechanism of action in the latter system, we tested its ability to compete for the binding of several opiates to brain membranes in vitro. Dynorphin1-13 inhibited the binding of all ligands examined, including dihydromorphine, D-Ala2-D-Leu5-enkephalin, ethylketacyclazocine (EKC) and naloxone. In all cases, it reduced the number of high affinity sites and, in the case of EKC, it also increased the Kd. We conclude that the mechanism of dynorphin inhibition is not simple rapidly reversible competition and is certainly not identical with respect to all opiate ligands.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6329465     DOI: 10.1016/0006-8993(84)90256-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  4 in total

Review 1.  Central non-opioid physiological and pathophysiological effects of dynorphin A and related peptides.

Authors:  V K Shukla; S Lemaire
Journal:  J Psychiatry Neurosci       Date:  1992-09       Impact factor: 6.186

Review 2.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

3.  Mathematical modeling of opiate binding to mouse brain membrane.

Authors:  H D Landahl; J Garzón; N M Lee
Journal:  Bull Math Biol       Date:  1985       Impact factor: 1.758

4.  A direct chemical interaction between dynorphin and excitatory amino acids.

Authors:  A Woods; A Zangen
Journal:  Neurochem Res       Date:  2001-04       Impact factor: 3.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.